News
NMRA
0.4289
-0.95%
-0.0041
Weekly Report: what happened at NMRA last week (1102-1106)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/06 21:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/03 17:05
Weekly Report: what happened at NMRA last week (1026-1030)?
Weekly Report · 11/02 09:23
Neumora Therapeutics Faces Nasdaq Minimum Bid Price Warning
TipRanks · 10/30 21:07
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/27 21:05
Weekly Report: what happened at NMRA last week (1019-1023)?
Weekly Report · 10/26 09:22
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/23 21:05
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 10/19 21:05
Weekly Report: what happened at NMRA last week (1012-1016)?
Weekly Report · 10/19 09:23
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/15 17:05
Weekly Report: what happened at NMRA last week (1005-1009)?
Weekly Report · 10/12 09:24
Weekly Report: what happened at NMRA last week (0928-1002)?
Weekly Report · 10/05 09:24
Weekly Report: what happened at NMRA last week (0921-0925)?
Weekly Report · 09/28 09:23
Weekly Report: what happened at NMRA last week (0914-0918)?
Weekly Report · 09/21 09:23
Weekly Report: what happened at NMRA last week (0907-0911)?
Weekly Report · 09/14 09:24
Weekly Report: what happened at NMRA last week (0831-0904)?
Weekly Report · 09/07 09:22
Weekly Report: what happened at NMRA last week (0824-0828)?
Weekly Report · 08/31 09:24
Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher
Simply Wall St · 08/29 12:00
More
Webull provides a variety of real-time NMRA stock news. You can receive the latest news about Neumora Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).